Clinician's Roundtable

Closer collaboration between nephrologists and pathologists is essential for optimizing the diagnosis and management of IgA nephropathy (IgAN). Hear from Dr. Anjay Rastogi as he highlights how pathology insights, clinical context, and ongoing communication can improve interpretation of kidney biopsy findings and support more informed treatment decisions. He's a Professor of Medicine and Clinical Chief of Nephrology at the David Geffen School of Medicine at UCLA, as well as the Director of the UCLA CORE Kidney Health Program.

Managing IgA nephropathy (IgAN) is becoming increasingly complex. In this episode, Dr. Anjay Rastogi explains why an expert opinion—not simply a second opinion—can help clinicians confirm diagnoses, optimize treatment decisions, and connect appropriate patients with specialized care and emerging therapeutic opportunities. Dr. Rastogi is a Professor of Medicine and Clinical Chief of Nephrology at the David Geffen School of Medicine at UCLA. He's also the Director of the UCLA CORE Kidney Health Program.

The biggest challenge in diagnosing nontuberculous mycobacterial (NTM) lung disease isn't confirmation; it's thinking to look for NTM in the first place. In this conversation with Dr. Brian McDonough, Dr. Doreen Addrizzo-Harris examines the subtle clinical and radiographic features that can help identify NTM earlier, discusses best practices for obtaining diagnostic cultures, and reviews how guideline-based criteria can help distinguish active disease from colonization. Dr. Addrizzo-Harris is the Fiona and Stanley Druckenmiller Professor of Pulmonary, Critical Care, and Sleep Medicine at NYU Grossman School of Medicine, as well as the Director of the Bronchiectasis and NTM Program at NYU Langone Health.

Even as our understanding of nontuberculous mycobacterial (NTM) lung disease advances, major gaps remain, from defining meaningful treatment success to overcoming innate drug resistance. In this conversation with Dr. Alexandria May, Dr. David Griffith shares his perspective on how recent evidence is shaping treatment decisions for these patients and explains why significant unmet needs persist. Dr. Griffith is a Professor of Medicine in the Division of Mycobacterial and Respiratory Infections within the Department of Medicine at National Jewish Health in Denver.

What do large registry data reveal about outcomes after intraocular foreign body removal, and how should those findings shape surgical planning and patient counseling? In this episode of New Retina Radio Journal Club with VBS, Jordan Deaner, MD, moderates a discussion with Vaidehi Dedania, MD, and Rehan Hussain, MD, on a 2025 IRIS Registry analysis of nearly 4,800 eyes. The group reviews the delayed timeline of visual recovery, the risk of late complications, and practical guidance on staging surgical intervention and setting realistic expectations in complex trauma cases.

Does socioeconomic status influence outcomes in proliferative sickle retinopathy? In this episode of Clinical Minute: Retina, host Maria Berrocal, MD, speaks with Audina "Nina" Berrocal, MD, of Bascom Palmer Eye Institute, who published a retrospective review of more than 100 patients with proliferative sickle retinopathy. They explore whether the integrated care model at Bascom Palmer may account for results that don't translate to other parts of the country. The conversation also touches on newborn screening programs in Florida and the importance of sickle cell centers in high-incidence communities.

Scientific uncertainty is inevitable, but how we communicate it matters. Dr. Jason Goldman, President of the American College of Physicians and liaison to the CDC Advisory Committee on Immunization Practices, shares strategies for discussing the unknown with patients transparently and effectively.

In patients with nontuberculous mycobacterial (NTM) lung disease, treatment decisions rarely follow a one-size-fits-all approach. In this expert-led discussion, Dr. Kenneth Olivier and Dr. Shelby MacRae join Dr. Charles Turck to explore how disease characteristics, patient priorities, and evolving clinical factors can inform individualized treatment strategies across the NTM care continuum. Dr. Olivier is the Michael E. Hatcher Distinguished Professor of Medicine, Microbiology, and Immunology at the University of North Carolina School of Medicine, where he also serves as Research Director of the Bronchiectasis and NTM Care and Research Center. Dr. MacRae is an Assistant Professor of Pulmonary and Critical Care Medicine and Director of the Environmental Lung Disease, Bronchiectasis, and NTM Program at Louisiana State University Health Sciences Center in New Orleans.

Colorectal cancer is increasingly affecting younger adults, highlighting important gaps in current screening practices. Given this alarming trend, Dr. Christopher Cann discusses how rising incidence in patients under 50 challenges traditional screening thresholds and underscores the need for earlier risk assessment. He emphasizes the importance of family history, identifying high-risk individuals who may benefit from earlier screening, and maintaining a low threshold to evaluate persistent symptoms. Dr. Cann is an Assistant Professor in the Department of Hematology Oncology at Fox Chase Cancer Center in Philadelphia, where he's also the Director of the Young Adult Cancer Program.

Patient navigators play an increasingly vital role in improving colorectal cancer screening rates and closing gaps in preventive care. Beyond care coordination, they serve as key educators by identifying eligible patients, addressing barriers, and facilitating referrals for screening colonoscopy and other modalities. Learn more about how integrating patient navigation can enhance adherence and ultimately improve patient outcomes with Dr. Christopher Cann, Assistant Professor in the Department of Hematology Oncology and Director of the Young Adult Cancer Program at Fox Chase Cancer Center in Philadelphia.